Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1990 1
1991 1
1992 1
1993 1
1994 1
1995 1
1996 1
1997 2
1998 3
1999 7
2000 1
2001 2
2002 1
2003 3
2004 1
2005 1
2006 9
2007 7
2008 2
2009 4
2010 4
2011 3
2012 2
2013 4
2014 5
2015 9
2016 5
2017 7
2018 5
2019 5
2020 5
2021 4
2022 6
2023 2
2024 7
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

115 results

Results by year

Filters applied: . Clear all
Page 1
Bromfenac.
[No authors listed] [No authors listed] 2024 Sep 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2024 Sep 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000016 Free Books & Documents. Review.
Milk levels of bromfenac are likely to be low with the usual oral dosage, but milk levels have not been measured after higher injectable dosages. Use caution when using bromfenac in nursing mothers, especially with the injectable drug. Maternal use of bromfenac …
Milk levels of bromfenac are likely to be low with the usual oral dosage, but milk levels have not been measured after higher injecta …
Topical bromfenac in VEGF-driven maculopathies: topical review and meta-analysis.
Kulikov AN, Vasiliev AS, Kalinicheva YA, Maltsev DS. Kulikov AN, et al. BMC Ophthalmol. 2024 Aug 23;24(1):369. doi: 10.1186/s12886-024-03650-z. BMC Ophthalmol. 2024. PMID: 39180057 Free PMC article. Review.
In this review, we focused on the advantages of topical bromfenac as an adjunct to intravitreal anti-VEGF therapy in VEGF-driven maculopathies. ...Except for one study which reported better visual outcomes with combined treatment, no difference in visual acuity or clinical …
In this review, we focused on the advantages of topical bromfenac as an adjunct to intravitreal anti-VEGF therapy in VEGF-driven macu …
Treatment of Non-Infectious Corneal Injury: Review of Diagnostic Agents, Therapeutic Medications, and Future Targets.
Dang DH, Riaz KM, Karamichos D. Dang DH, et al. Drugs. 2022 Feb;82(2):145-167. doi: 10.1007/s40265-021-01660-5. Epub 2022 Jan 13. Drugs. 2022. PMID: 35025078 Free PMC article. Review.
While these medications are effective for controlling ocular inflammation, side effects, such as elevated intraocular pressure and cataract formation, must be monitored by clinicians. Non-steroidal medications, such as ketorolac, bromfenac, nepafenac, and diclofenac …
While these medications are effective for controlling ocular inflammation, side effects, such as elevated intraocular pressure and ca …
Efficacy and safety of bromfenac 0.075% formulated in DuraSite for pain and inflammation in cataract surgery.
Wentz SM, Price F, Harris A, Siesky B, Ciulla T. Wentz SM, et al. Expert Opin Pharmacother. 2019 Oct;20(14):1703-1709. doi: 10.1080/14656566.2019.1645834. Epub 2019 Jul 25. Expert Opin Pharmacother. 2019. PMID: 31343372 Review.
Introduction: Bromfenac is a topical ophthalmic non-steroidal anti-inflammatory drug (NSAID) used to reduce pain and treat post-operative inflammation after cataract surgery. Bromfenac 0.075% in the DuraSite vehicle is a newly-approved formulation which has been sho …
Introduction: Bromfenac is a topical ophthalmic non-steroidal anti-inflammatory drug (NSAID) used to reduce pain and treat post-opera …
Clinical pharmacokinetics and pharmacodynamics of bromfenac.
Skjodt NM, Davies NM. Skjodt NM, et al. Clin Pharmacokinet. 1999 Jun;36(6):399-408. doi: 10.2165/00003088-199936060-00002. Clin Pharmacokinet. 1999. PMID: 10427465 Review.
Bromfenac is a nonsteroidal anti-inflammatory drug whose peak plasma concentration is reached 0.5 hours after oral administration. ...Renal disease, hepatic disease and aging alter the disposition kinetics of bromfenac, and dosage adjustment may be advisable. Bro …
Bromfenac is a nonsteroidal anti-inflammatory drug whose peak plasma concentration is reached 0.5 hours after oral administration. .. …
Drug-induced hepatotoxicity.
Lee WM. Lee WM. N Engl J Med. 2003 Jul 31;349(5):474-85. doi: 10.1056/NEJMra021844. N Engl J Med. 2003. PMID: 12890847 Review. No abstract available.
Bromfenac-induced neurotrophic keratitis in a corneal graft.
Raj N, Panigrahi A, Alam M, Gupta N. Raj N, et al. BMJ Case Rep. 2022 Jul 11;15(7):e249400. doi: 10.1136/bcr-2022-249400. BMJ Case Rep. 2022. PMID: 35817488 Free PMC article.
On checking his medications, it was found that the patient was unknowingly using bromfenac drops in place of brimonidine tartrate for the past month. A diagnosis of neurotrophic keratitis was made in the setting of PK performed for viral keratitis, incited by use of topica …
On checking his medications, it was found that the patient was unknowingly using bromfenac drops in place of brimonidine tartrate for …
Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation.
Donnenfeld ED, Holland EJ, Stewart RH, Gow JA, Grillone LR; Bromfenac Ophthalmic Solution 0.09% (Xibrom) Study Group. Donnenfeld ED, et al. Ophthalmology. 2007 Sep;114(9):1653-62. doi: 10.1016/j.ophtha.2006.12.029. Epub 2007 Apr 19. Ophthalmology. 2007. PMID: 17445902 Clinical Trial.
The median time to resolution of ocular pain was 2 days (bromfenac) versus 5 days (placebo) (P<0.0001). Numbers of most ocular adverse events were lower for the bromfenac group than for the placebo group. ...There were no serious ocular adverse even …
The median time to resolution of ocular pain was 2 days (bromfenac) versus 5 days (placebo) (P<0.0001). Numbers of most ocular …
Bromfenac ophthalmic solution 0.07% dosed once daily for cataract surgery: results of 2 randomized controlled trials.
Walters TR, Goldberg DF, Peace JH, Gow JA; Bromfenac Ophthalmic Solution 0.07% Once Daily Study Group. Walters TR, et al. Ophthalmology. 2014 Jan;121(1):25-33. doi: 10.1016/j.ophtha.2013.07.006. Epub 2013 Sep 8. Ophthalmology. 2014. PMID: 24021896 Clinical Trial.

Fewer subjects in the bromfenac group (3.2%) discontinued investigational product early because of a lack of efficacy than in the placebo group (23.9%; P < 0.0001). The incidence of adverse events was significantly lower in the bromfenac 0.07% group compar

…
Fewer subjects in the bromfenac group (3.2%) discontinued investigational product early because of a lack of efficacy than in the pla …
115 results